See the published version of this preprint at BMC Ophthalmology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Liwei Ma
Fourth Affiliated Hospital of China Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7867-8060
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: A prospective cohort study was performed to evaluate whether the Optical Quality Analysis System (OQAS) can serve as a valuable additional indicator for appropriate posterior capsulotomy referral.
Methods: One hundred and five eyes from 96 patients undergoing capsulotomy were divided into precapsulotomy logMAR CDVA ≤ 0.1 group and logMAR CDVA > 0.1 group. CDVA， and the Visual Function 14 index (VF-14) score were estimated before and one month after capsulotomy. The objective scattering index (OSI) value was measured by using the OQAS. Posterior capsule opacification (PCO) severity was assessed with Evaluation of PCO 2000 (EPCO 2000) software.
Results：In logMAR CDVA > 0.1 group, the correlations of OSI, logMAR CDVA, EPCO score and VF-14 score were very strong preoperatively. In logMAR CDVA ≤ 0.1 group, preoperatively, OSI was correlated with logMAR CDVA (r = 0.451), EPCO score (r = 0.789), and VF-14 score (r = 0.852). LogMAR CDVA has weak correlation with VF-14 score (r = -0.384) and EPCO score (r = 0.566). VF-14 score was correlated with EPCO score (r = -0.669). In the logMAR CDVA ≤ 0.1 group, there was no significant difference in logMAR CDVA between precapsulotomy and postcapsulotomy (P > 0.05). In the two groups, all the other optical quality parameters were significantly improved after capsulotomy (P < 0.05). In logMAR CDVA > 0.1 group, the area under the curve of the ROC of the OSI was 0.996 (P = 0.000). In logMAR CDVA ≤ 0.1 group, the area under the curve of the ROC of the OSI was 0.943 (P = 0.000).
Conclusions：The OSI was useful for evaluating of PCO and prediction of beneficial capsulotomy. Especially for patients with slight PCO and better visual acuity, OSI is more valuable than CDVA and completely objective examination.
Trial registration: The study protocol was registered at the Chinese Clinical Trial Registry. Register: ChiCTR1800018842 (Registered Date: October 13th, 2018).
Keywords
Posterior capsule opacification, Objective scattering index, Capsulotomy, Visual Function 14 index, Visual outcomes
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Ophthalmology.
No community comments so far
Editorial decision: Accept
On 28 Oct, 2020
Editor assigned
On 26 Oct, 2020
Submission checks complete
On 25 Oct, 2020
Editor invited
On 25 Oct, 2020
Version 2
Posted 23 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 13 Oct, 2020
Reviewer #1 agreed
On 26 Sep, 2020
Reviewer #2 agreed
On 26 Sep, 2020
Review #1 received
Received 26 Sep, 2020
Review #2 received
Received 26 Sep, 2020
Reviewers invited
Invitations sent on 23 Sep, 2020
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Major revision
On 29 Jul, 2020
Review #2 received
Received 06 Jul, 2020
Reviewer #2 agreed
On 02 Jul, 2020
Review #1 received
Received 03 Feb, 2020
Reviewers invited
Invitations sent on 31 Oct, 2019
Reviewer #1 agreed
On 31 Oct, 2019
Submission checks complete
On 03 Oct, 2019
Editor assigned
On 02 Oct, 2019
Editor invited
On 01 Oct, 2019
First submitted
On 30 Sep, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Ophthalmology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Ophthalmology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Liwei Ma
Fourth Affiliated Hospital of China Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7867-8060
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Ophthalmology.
No community comments so far
Editorial decision: Accept
On 28 Oct, 2020
Editor assigned
On 26 Oct, 2020
Submission checks complete
On 25 Oct, 2020
Editor invited
On 25 Oct, 2020
Version 2
Posted 23 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 13 Oct, 2020
Reviewer #1 agreed
On 26 Sep, 2020
Reviewer #2 agreed
On 26 Sep, 2020
Review #1 received
Received 26 Sep, 2020
Review #2 received
Received 26 Sep, 2020
Reviewers invited
Invitations sent on 23 Sep, 2020
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Major revision
On 29 Jul, 2020
Review #2 received
Received 06 Jul, 2020
Reviewer #2 agreed
On 02 Jul, 2020
Review #1 received
Received 03 Feb, 2020
Reviewers invited
Invitations sent on 31 Oct, 2019
Reviewer #1 agreed
On 31 Oct, 2019
Submission checks complete
On 03 Oct, 2019
Editor assigned
On 02 Oct, 2019
Editor invited
On 01 Oct, 2019
First submitted
On 30 Sep, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Ophthalmology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Ophthalmology.
Background: A prospective cohort study was performed to evaluate whether the Optical Quality Analysis System (OQAS) can serve as a valuable additional indicator for appropriate posterior capsulotomy referral.
Methods: One hundred and five eyes from 96 patients undergoing capsulotomy were divided into precapsulotomy logMAR CDVA ≤ 0.1 group and logMAR CDVA > 0.1 group. CDVA， and the Visual Function 14 index (VF-14) score were estimated before and one month after capsulotomy. The objective scattering index (OSI) value was measured by using the OQAS. Posterior capsule opacification (PCO) severity was assessed with Evaluation of PCO 2000 (EPCO 2000) software.
Results：In logMAR CDVA > 0.1 group, the correlations of OSI, logMAR CDVA, EPCO score and VF-14 score were very strong preoperatively. In logMAR CDVA ≤ 0.1 group, preoperatively, OSI was correlated with logMAR CDVA (r = 0.451), EPCO score (r = 0.789), and VF-14 score (r = 0.852). LogMAR CDVA has weak correlation with VF-14 score (r = -0.384) and EPCO score (r = 0.566). VF-14 score was correlated with EPCO score (r = -0.669). In the logMAR CDVA ≤ 0.1 group, there was no significant difference in logMAR CDVA between precapsulotomy and postcapsulotomy (P > 0.05). In the two groups, all the other optical quality parameters were significantly improved after capsulotomy (P < 0.05). In logMAR CDVA > 0.1 group, the area under the curve of the ROC of the OSI was 0.996 (P = 0.000). In logMAR CDVA ≤ 0.1 group, the area under the curve of the ROC of the OSI was 0.943 (P = 0.000).
Conclusions：The OSI was useful for evaluating of PCO and prediction of beneficial capsulotomy. Especially for patients with slight PCO and better visual acuity, OSI is more valuable than CDVA and completely objective examination.
Trial registration: The study protocol was registered at the Chinese Clinical Trial Registry. Register: ChiCTR1800018842 (Registered Date: October 13th, 2018).
Figure 1
Figure 2
Figure 3
Figure 4
Loading...